Grail: Bob Ragusa, Hans Bishop
Illumina has appointed Bob Ragusa as CEO of its subsidiary Grail. He succeeds Hans Bishop, who will serve as advisor to the CEO through the end of 2021 and then step down.
Ragusa is Illumina's chief operations officer, a role in which he helped scale the business globally. He was responsible for the company's clinical lab services, supply chain, quality, life cycle management, information technology, global facilities, and real estate teams.
Prior to Illumina, he was executive VP of engineering and global operations at Accuray, a radiation oncology company, and senior VP of global operations at Applied Biosystems.
Ragusa holds a master's degree in biomedical and electrical engineering from Carnegie Mellon University and an MBA from the University of Connecticut.
Bishop joined Grail's board of directors in 2018 before becoming CEO. He founded Juno Therapeutics in 2013 and was the firm's president and CEO until it was acquired by Celgene. He serves on the boards of Celgene and Agilent Technologies.